Everything below concerns synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
=== Lactones === gamma-Decalactone intense peach flavor gamma-Nonalactone coconut odor, popular in suntan lotions delta-Octalactone creamy note Jasmine lactone powerful fatty-fruity peach and apricot Massoia lactone powerful creamy coconut Wine lactone sweet coconut odor Sotolon (maple syrup, curry, fenugreek)
=== Pusha T's feud with Jim Jones === Rapper Jim Jones made headlines in 2023 for questioning Pusha T's placement in a top fifty rappers of all-time list on the RapCaviar podcast. He repeated his stance during an interview on radio show The Breakfast Club. Pusha T's verse on "Chains & Whips", the first song from Let God Sort Em Out teased at a Louis Vuitton fashion show in 2023, was reported as a response to Jones; in the lyrics, Pusha T accused Jones of jealousy and implied that his comments were made to cosy up to Drake, Pusha T's rival who had brought Jones out as a guest at a concert shortly before the RapCaviar interview. Jones reignited the feud after the release of the lead single "Ace Trumpets" in 2025: "I don't believe it, I don't believe them." When asked about the feud in June 2025, Pusha T responded: "I personally never understood what the interviews were about [...] or why my name kept coming up. It's one thing to keep saying I'm not a top fifty MC, but it's another thing for you not to say that you [yourself] are one. No one asked me about a top fifty nothing. After about the third interview, I promise you, I said, 'Man, he must really want me to know what he thinks about me.' And that's how [my] verse came. This is what I really think about him. This is what I really think about him. Every line is my true heart."
Lipid vesicles or liposomes are approximately spherical pockets that are enclosed by a lipid bilayer. These structures are used in laboratories to study the effects of chemicals in cells by delivering these chemicals directly to the cell, as well as getting more insight into cell membrane permeability. Lipid vesicles and liposomes are formed by first suspending a lipid in an aqueous solution then agitating the mixture through sonication, resulting in a vesicle. Measuring the rate of efflux from the inside of the vesicle to the ambient solution allows researchers to better understand membrane permeability. Vesicles can be formed with molecules and ions inside the vesicle by forming the vesicle with the desired molecule or ion present in the solution. Proteins can also be embedded into the membrane through solubilizing the desired proteins in the presence of detergents and attaching them to the phospholipids in which the liposome is formed. These provide researchers with a tool to examine various membrane protein functions.
Sources: en.wikipedia.org
Naturally occurring niobium (41Nb) is composed of one stable isotope (93Nb). The most stable radioisotope is 92Nb with a half-life of 34.7 million years, followed by 94Nb at a half-life of 20,400 years and 91Nb at 680 years. Other radioisotopes that have been synthesized range from 82Nb to 110Nb; these have half-lives that are less than two hours, except 95Nb (34.991 days), 96Nb (23.35 hours) and 90Nb (14.60 hours). The most stable of the meta states is 93mNb with excitation energy 31 keV and a 16.1 year half-life; this is produced in the decay of 93Zr. The primary decay mode before stable 93Nb is electron capture to zirconium isotopes and the primary mode after is beta emission, with delayed neutron emission starting at 104Nb, leading to molybdenum isotopes. Only 95Nb, along with 97Nb (72 minutes) and heavier isotopes (seconds) are fission products in significant quantity, as the other isotopes are shadowed by stable or very long-lived (93) isotopes of the preceding element zirconium from the usual mode of production through beta decay of neutron-rich fission fragments. 95Nb is the decay product of 95Zr (64 days), so disappearance of 95Nb in used nuclear fuel is slower than would be expected from its own 35-day half-life alone.
=== Rehabituation to dairy products === Regular consumption of dairy foods containing lactose can promote a colonic bacteria adaptation, enhancing a favorable microbiome, which allows people with primary lactase deficiency to diminish their intolerance and to consume more dairy foods. The way to induce tolerance is based on progressive exposure, consuming smaller amounts frequently, distributed throughout the day. Lactose intolerance can also be managed by ingesting live yogurt cultures containing lactobacilli that are able to digest the lactose in other dairy products.
== Career == Vasquez began his career as the business editor for the Las Cruces Bulletin from 2008 to 2011. He later served as executive director of the Las Cruces Hispanic Chamber of Commerce before joining SDS Inc. as executive vice president for public relations. From 2013 to 2015, Vasquez worked as a field representative for U.S. Senator Martin Heinrich. He also worked as vice president of communications for First Focus on Children, director of community relations for the New Mexico Wildlife Federation, and deputy state director for the Wilderness Society. He later worked as deputy director for federal lands at the Western Conservation Foundation from 2019 to 2021. In 2017, Vasquez was elected to the Las Cruces City Council, where he served until 2021.
Sources: en.wikipedia.org
High doses of some antioxidants may have harmful long-term effects. The Beta-Carotene and Retinol Efficacy Trial (CARET) study of lung cancer patients found that smokers given supplements containing beta-carotene and vitamin A had increased rates of lung cancer. These harmful effects may also be seen in non-smokers, as one meta-analysis including data from approximately 230,000 patients showed that β-carotene, vitamin A or vitamin E supplementation is associated with increased mortality, but saw no significant effect from vitamin C. No health risk was seen when all the randomized controlled studies were examined together, but an increase in mortality was detected when only high-quality and low-bias risk trials were examined separately. As the majority of these low-bias trials dealt with either elderly people, smokers, or people with disease, these results may not apply to the general population. This meta-analysis was later repeated and extended by the same authors, confirming the previous results. These two publications are consistent with some previous meta-analyses that also suggested that vitamin E supplementation increased mortality, and that antioxidant supplements increased the risk of colon cancer. In the Selenium and Vitamin E Cancer Prevention Trial (SELECT study), vitamin E – alone or combined with selenium – had no effect on the risk of prostate cancer. Beta-carotene may also increase lung cancer.
=== South Asia === In South Asia, the color of one's skin determined social status as it implied the circumstances of one's positionality. While pale skin suggested being away from the sun, darker skin signified the result of working in external conditions. With colonial influence from Britain's occupation, there was a distinction in superiority and inferiority. With those in power attributing pale complexions, there was an association tied among class and position. The South Asian film industry was a contributing factor from colonialism in the reinforcement of these narratives. Turmeric was a used ingredient in lightening skin tone complexion to be seen as desirable.
=== Aortic regurgitation === Aortic regurgitation is treated with aortic valve replacement, which is recommended in patients with symptomatic severe aortic regurgitation. Aortic valve replacement is also recommended in patients that are asymptomatic but have chronic severe aortic regurgitation and left ventricular ejection fraction of less than 50%. Hypertension is treated in patients with chronic aortic regurgitation, with the anti-hypersensives of choice being calcium channel blockers, ACE inhibitors, or ARBs. Also, endocarditis prophylaxis is indicated before dental, gastrointestinal or genitourinary procedures. Mild to moderate aortic regurgitation should be followed with echocardiography and a cardiac stress test once every 1–2 years. In severe moderate/severe cases, patients should be followed with echocardiography and cardiac stress test and/or isotope perfusion imaging every 3–6 months.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.